IRIS
CAROTENUTO, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.757
EU - Europa 1.181
AS - Asia 649
AF - Africa 37
SA - Sud America 6
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.633
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.729
IT - Italia 549
SG - Singapore 380
DE - Germania 197
CN - Cina 195
NL - Olanda 126
IE - Irlanda 65
FI - Finlandia 60
UA - Ucraina 49
GB - Regno Unito 41
CI - Costa d'Avorio 37
IN - India 36
CA - Canada 28
VN - Vietnam 24
FR - Francia 23
RU - Federazione Russa 22
SE - Svezia 12
BE - Belgio 6
CZ - Repubblica Ceca 5
CL - Cile 4
IR - Iran 4
LT - Lituania 4
MK - Macedonia 4
ES - Italia 3
HK - Hong Kong 3
PT - Portogallo 3
AU - Australia 2
GR - Grecia 2
JP - Giappone 2
PL - Polonia 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
AT - Austria 1
BG - Bulgaria 1
CH - Svizzera 1
EU - Europa 1
HR - Croazia 1
KH - Cambogia 1
MT - Malta 1
NO - Norvegia 1
QA - Qatar 1
TH - Thailandia 1
TR - Turchia 1
VE - Venezuela 1
Totale 3.633
Salva come PNG Salva come JPEG
Città #
Chandler 309
Singapore 306
Santa Clara 207
Ashburn 138
Amsterdam 120
Naples 118
Millbury 77
Beijing 61
Des Moines 55
Napoli 50
Nanjing 38
Princeton 37
Lawrence 36
Krefeld 33
Boston 32
Norwalk 28
Milan 25
Seattle 25
Dong Ket 24
Helsinki 20
Pune 17
Rome 16
Rottweil 15
Wilmington 15
Ottawa 14
Dallas 13
Dublin 13
Cava De' Tirreni 12
Lappeenranta 11
Formia 9
Nanchang 9
Bari 8
Council Bluffs 8
Jiaxing 8
Shenyang 8
Toronto 8
Redwood City 7
Sant'arpino 7
Washington 7
Brussels 6
Hebei 6
Houston 6
London 6
Los Angeles 6
Munich 6
Boardman 5
Caposele 5
Catania 5
Frankfurt am Main 5
Mountain View 5
New York 5
Tianjin 5
Turin 5
Dearborn 4
Fairfield 4
Falkenstein 4
Massa 4
Schashagen 4
Shanghai 4
Springfield 4
Suffern 4
Trapani 4
Augusta 3
Brusciano 3
Casoria 3
Changsha 3
Hong Kong 3
Kronberg 3
Lizzanello 3
Menlo Park 3
Moscow 3
Paris 3
Prague 3
Prineville 3
Qualiano 3
Serre 3
Sesto San Giovanni 3
Shenzhen 3
Torre Annunziata 3
Ann Arbor 2
Arcore 2
Basildon 2
Bologna 2
Borgaro Torinese 2
Calvizzano 2
Caserta 2
Chengdu 2
Darmstadt 2
Espoo 2
Genoa 2
Glasgow 2
Grottaferrata 2
Hefei 2
Jinan 2
Lisbon 2
Marratxí 2
Marsala 2
Mumbai 2
Rapallo 2
San Mateo 2
Totale 2.149
Salva come PNG Salva come JPEG
Nome #
AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature 167
2D linear measures of ventricular enlargement may be relevant markers of brain atrophy and long-term disability progression in multiple sclerosis 76
Uric acid in relapsing–remitting multiple sclerosis: a 2-year longitudinal study 75
Coenzyme Q10 supplementation reduces peripheral oxidative stress and inflammation in interferon-β1a-treated multiple sclerosis 73
The effects of mechanical focal vibration on walking impairment in multiple sclerosis patients: A randomized, double-blinded vs placebo study 69
Quality of life and cognitive function in pediatric and young multiple sclerosis patients: a cross-sectional study 67
Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy) 63
Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis 62
The use of medical-grade cannabis in patients non-responders to Nabiximols 57
Assessment of retinal vascular network in amnestic mild cognitive impairment by optical coherence tomography angiography 55
Anatomical and functional retinal changes in multiple sclerosis 53
A 8-year retrospective cohort study comparing Interferon-beta formulations for relapsing-remitting multiple sclerosis 53
Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study 52
Normative values of the Rao’s Brief Repeatable Battery in an Italian young adolescent population: the influence of age, gender, and education 51
Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression 49
Uric acid: a potential biomarker of multiple sclerosis and of its disability 48
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 48
Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a 48
CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients 47
Pragmatic abilities in multiple sclerosis: The contribution of the temporo-parietal junction 47
Retinal vascular density in multiple sclerosis: a one year follow up 45
Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment 45
A 8-year retrospective cohort study comparing Interferon-β formulations for relapsing-remitting multiple sclerosis 45
Can people with multiple sclerosis actually understand what they read in the Internet age? 44
Communication in Multiple Sclerosis: Pragmatic Deficit and its Relation with Cognition and Social Cognition 44
Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 44
Inhibition of oligodendrocyte differentiation by immunoglobulin purified from serum of multiple sclerosis patients during relapse 43
Assessment of neuroactive steroids in cerebrospinal fluid comparing acute relapse and stable disease in relapsing-remitting multiple sclerosis 43
The IFN-β 1b effect on Cu Zn superoxide dismutase (SOD1) in peripheral mononuclear blood cells of relapsing-remitting multiple sclerosis patients and in neuroblastoma SK-N-BE cells 42
Peripapillary Vessel Density as Early Biomarker in Multiple Sclerosis 42
A longitudinal real-life comparison study of natalizumab and fingolimod 41
Cognitive trajectories in multiple sclerosis: a long-term follow-up study 41
Grey:white matter ratio at diagnosis and the risk of 10-year multiple sclerosis progression 40
Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing–Remitting Multiple Sclerosis 40
Biochemical parameters alterations in multiple sclerosis: a longitudinal study and review of the literature. 40
Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis 40
Changes in lymphocytes, neutrophils and immunoglobulins in year-1 cladribine treatment in multiple sclerosis 39
Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy 39
Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex(®) 39
Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis 39
The Framingham cardiovascular risk score in multiple sclerosis 38
Botulinum toxin for the management of spasticity in multiple sclerosis: the Italian botulinum toxin network study 37
COVID-19 pandemic and mental distress in Multiple Sclerosis: implications for clinical management 37
Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis 37
Healthcare Costs for Treating Relapsing Multiple Sclerosis and the Risk of Progression: A Retrospective Italian Cohort Study from 2001 to 2015 36
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study 36
A retrospective exploratory analysis on cardiovascular risk and cognitive dysfunction in multiple sclerosis 36
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study 35
Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies 35
Teeth loss after teriflunomide treatment: Casual or causal? A short case series 33
Mental Health in Multiple Sclerosis During the COVID-19 Outbreak: A Delicate Balance between Fear of Contagion and Resilience 33
Emergency medical care for multiple sclerosis: A five-year population study in the Campania Region (South Italy) 33
Concomitant diagnosis of multiple sclerosis and human immunodeficiency virus (HIV) infection: case report and the review of literature 31
Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisions 31
The independent contribution of brain, spinal cord and gadolinium MRI in treatment decision in multiple sclerosis: A population-based retrospective study 31
Tango classes in people with Multiple Sclerosis (PwMS): Impact on motor and non-motor functions 30
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis 30
Cardiovascular profile improvement during Natalizumab treatment 30
Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis 29
Olfactory function and cognition in relapsing–remitting and secondary-progressive multiple sclerosis 29
Predictors of Nabiximols (Sativex®) discontinuation over long-term follow-up: a real-life study 29
Interplay Between Cognitive and Bowel/Bladder Function in Multiple Sclerosis 29
Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020 28
The Framingham cardiovascular risk score and 5-year progression of multiple sclerosis 28
ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial 28
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 27
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosis 27
Necrotizing skin lesion and radial nerve palsy in a patient treated with glatiramer acetate. 26
Grey/white matter ratio at diagnosis, and the risk of 10-year multiple sclerosis progression 26
Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg 26
Needs and Experiences of Children and Adolescents with Pediatric Multiple Sclerosis and Their Caregivers: A Systematic Review 25
Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice. 25
Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data 25
Quality of Life Changes in Early-Onset Multiple Sclerosis: A 4-Year Follow-Up Study 24
Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study 24
Vitamin K cream reduces reactions at the injection site in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon beta - VIKING study 24
Serpentine tongue in long-term metoclopramide treatment 23
The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis 22
Correction to: Concomitant diagnosis of multiple sclerosis and human immunodeficiency virus (HIV) infection: case report and the review of literature 22
Optical coherence tomography angiography retinal vascular network assessment in multiple sclerosis 22
Exploring the relation between reserve and fatigue in multiple sclerosis 21
Persistence with Botulinum Toxin Treatment for Spasticity Symptoms in Multiple Sclerosis 21
Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic Review 21
Idiopathic intracranial hypertension in a patient with thyroid papillary carcinoma 21
Neuroimaging correlates of cognitive dysfunction in adults with multiple sclerosis 21
Editorial: Cognition in Multiple Sclerosis 20
[18F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis 20
ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis 20
Growth hormone/IGF-1 axis longitudinal evaluation in clinically isolated syndrome patients on interferon β-1b therapy: stimulation tests and correlations with clinical and radiological conversion to multiple sclerosis 20
Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis 20
Epidemiological and Immune Profile Analysis of Italian Subjects with Endometriosis and Multiple Sclerosis 19
Clinical correlates of R1 relaxometry and magnetic susceptibility changes in multiple sclerosis: a multi-parameter quantitative MRI study of brain iron and myelin 19
Google Maps Timeline: An open-access digital tool to monitor walking abilities in people with multiple sclerosis 19
Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy 18
Therapeutic lag in reducing disability progression in relapsing-remitting multiple sclerosis: 8-year follow-up of two randomized add-on trials with atorvastatin 18
Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years 17
Epidemiology of multiple sclerosis in the Campania Region (Italy): Derivation and validation of an algorithm to calculate the 2015-2020 incidence 17
Diagnostic challenges of Parkinsonism occurring in multiple sclerosis 17
A real-world study of alemtuzumab in a cohort of Italian patients 16
Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications 16
Totale 3.653
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.839
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.839
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020143 0 0 0 0 0 0 13 13 12 50 43 12
2020/2021233 20 7 12 34 47 11 9 5 24 11 20 33
2021/2022467 8 1 4 6 11 36 8 17 58 34 105 179
2022/20231.000 81 87 20 43 87 125 152 53 152 132 45 23
2023/2024678 32 96 84 56 41 85 17 71 21 17 101 57
2024/2025859 182 179 32 72 132 251 11 0 0 0 0 0
Totale 3.932